HAN W TUN
Physician at San Pablo Rd, Jacksonville, FL
License number
Florida 265
Issued Date
Aug 11, 1998
Effective Date
Jun 15, 2000
Expiration Date
Jun 5, 2000
Category
Health Care
Type
Registration for Resident/HSE Physician
Address
Address
4500 San Pablo Rd, Jacksonville, FL 32224
Phone
(904) 953-3729
Personal information
See more information about HAN W TUN at radaris.comName
Address
Phone
4512 E Seneca Dr, Jacksonville, FL 32259
7717 Watermark Ln, Jacksonville, FL 32256
717 Fair Oaks Ln, Jacksonville, FL 32259
4512 Seneca Dr, Jacksonville, FL 32259
10023 Belle Rive Ct, Jacksonville, FL 32256
Professional information
Dr. Han W Tun, Jacksonville FL - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
Mayo Clinic
4500 San Pablo Rd S, Jacksonville 32224
(904) 953-2000 (Phone)
4500 San Pablo Rd S, Jacksonville 32224
(904) 953-2000 (Phone)
Certifications:
Hematology, 2001, Internal Medicine, 1998, Medical Oncology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mayo Clinic
4500 San Pablo Rd S, Jacksonville 32224
Mayo Clinic
4500 San Pablo Rd, Jacksonville 32224
4500 San Pablo Rd S, Jacksonville 32224
Mayo Clinic
4500 San Pablo Rd, Jacksonville 32224
Han Tun, Jacksonville FL
Work:
Mayo Clinic hospital
4500 San Pablo Rd S, Jacksonville, FL 32224
4500 San Pablo Rd S, Jacksonville, FL 32224
Combination Therapy For Chemoresistant Cancers
US Patent:
2013024, Sep 19, 2013
Filed:
Sep 26, 2012
Appl. No.:
13/627848
Inventors:
Han Win Tun - Jacksonville FL, US
Simon James Cooper - Jacksonville FL, US
Laura Ann Marlow - Jacksonville FL, US
Simon James Cooper - Jacksonville FL, US
Laura Ann Marlow - Jacksonville FL, US
Assignee:
Celgene Corporation - Summit NJ
International Classification:
A61K 38/00, C12Q 1/68, G01N 33/574, A61K 31/706
US Classification:
514 199, 435 612, 435 792, 435 74
Abstract:
Methods of treating, preventing or managing triple negative breast cancer (TNBC) or clear cell renal cell carcinoma (ccRCC) are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin in combination with a cytidine analog. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.